INDEX
A
Actinobacillus pleuropneumoniae ....................... 205, 206,
211, 315
Adenovirus (Ad)..................................252, 357–365, 368
Adjuvants .......................... 250, 254, 391, 405–421, 424,
425, 431, 439, 462, 492, 513–515, 519, 521,
525, 526, 538, 545, 550, 551, 556
Alcian blue/silver staining .......................... 316, 318, 326
Alphavirus vectors ....................................... 64, 66, 69, 78
Aluminum salts........................................ 3, 254, 489–497
Antibodies ................................. 4, 5, 7, 9–27, 44, 51–53,
65, 66, 73–75, 77, 86, 88, 90–93, 189, 198, 200,
201, 242, 249, 251, 253, 254, 267, 335–337,
340, 344–347, 351, 357, 358, 368, 395, 400,
406–408, 411, 414–420, 424, 425, 427, 428,
431, 432, 442, 470, 471, 485, 486, 490, 501,
504, 507, 510, 515, 519, 521, 522, 526,
528–531, 537, 538, 541–546, 549, 550, 556,
559–573, 575, 576
Antigen delivery ................................................... 461–474
Antigen production................................. 78, 95–117, 461
Antigens................................................ 3–7, 9–11, 19, 20,
30, 43–58, 63–79, 83–93, 119–134, 206, 223,
250, 252–256, 258, 259, 305–311, 313–328,
395, 400, 405, 414, 419–421, 423, 425, 426,
428, 431, 432, 439, 440, 448, 461, 462,
465–467, 469, 470, 473, 474, 477–486, 489,
492–494, 496, 501–504, 507, 509, 513–523,
526, 531, 534, 537, 538, 540, 541, 544, 546,
550, 551
Antigen-specific ......................................20, 21, 419, 428,
490, 513, 514, 525–535, 537–546, 550
Antigen-specific CD8+ T cell killing............................ 550
Antigen uptake ..................................................... 462, 514
Attenuation.............................2, 252, 259, 260, 331–353
B
Bacteria .......................2, 3, 7, 11, 16, 19, 20, 44, 52–55,
107, 191, 193, 249, 250, 252–256, 259, 267,
268, 276, 331, 333, 342, 343, 413, 420, 429,
450–452, 458, 461, 462, 472, 478, 479, 559–573
Baculovirus expression vector system
(BEVS) ....................................... 95–117, 368, 376
B-cell ....................... 4, 5, 25–27, 43, 45, 53, 56, 84, 559
Biomaterials .......................................................... 461, 462
C
Cancer vaccines ..............................................65, 256, 305
Capsular polysaccharide (CPS)................... 253, 254, 478
Capsule polymerases ............................................ 313–328
Carrier protein.................................... 267–303, 305–311,
313, 315, 477
Cell cultivation ...........................101, 106, 108, 112, 376
Cell-penetrating peptides (CPPs) ...............................358,
359, 364
Cell recruitment ................................................... 513–523
Cell therapy ................................................................... 369
Cellular immunity ............................................5, 415, 448
Centrifugation ................................. 69, 87, 89, 184, 189,
191, 193, 194, 197, 198, 210, 220, 226, 231,
239, 243, 276, 280, 327, 342, 348, 371, 380,
385, 433, 468, 470, 472, 480, 483, 485, 522,
571, 572, 584
Chlamydia.........................................................19, 20, 257
Chromatography ....................................75, 76, 120, 121,
123, 126–128, 133, 189, 199, 212, 220–222,
235, 236, 240, 241, 268, 271, 273, 274, 281,
301, 302, 316, 317, 328, 333, 342, 371, 474
Codon optimization ...........................199, 406, 411, 420
Computational antigen discovery ............................29–41
Conjugated vaccines ..................................................... 254
Conjugation ............................................. 6, 12, 267–302,
305–311, 363, 478
Cryogenic TEM (cryo-TEM)............................. 499–501,
503–510
Cytotoxicity .......................................................... 549–558
Cytotoxic T lymphocyte (CTL) ......................... 407, 420,
550–552, 554
D
Dicarboxylic acid linkers ...................................... 306–308
Dielectric spectroscopy (DS) ................................ 96, 102,
106, 218, 220, 232, 233, 239
Diseases........................................1, 2, 6, 7, 48, 117, 249,
251–254, 256, 257, 259, 260, 313, 331, 332,
367, 369, 370, 391, 407, 421, 424, 448, 461,
473, 477, 478, 494, 513, 525, 537, 559, 576
DNA delivery ................................................................ 448
DNA vaccines ............................ 357, 391–402, 405–421,
439–442, 444, 448
Blaine A. Pfeifer and Andrew Hill (eds.), Vaccine Delivery Technology: Methods and Protocols, Methods in Molecular Biology,
vol. 2183, https://doi.org/10.1007/978-1-0716-0795-4, © Springer Science+Business Media, LLC, part of Springer Nature 2021
587
A
Actinobacillus pleuropneumoniae ....................... 205, 206,
211, 315
Adenovirus (Ad)..................................252, 357–365, 368
Adjuvants .......................... 250, 254, 391, 405–421, 424,
425, 431, 439, 462, 492, 513–515, 519, 521,
525, 526, 538, 545, 550, 551, 556
Alcian blue/silver staining .......................... 316, 318, 326
Alphavirus vectors ....................................... 64, 66, 69, 78
Aluminum salts........................................ 3, 254, 489–497
Antibodies ................................. 4, 5, 7, 9–27, 44, 51–53,
65, 66, 73–75, 77, 86, 88, 90–93, 189, 198, 200,
201, 242, 249, 251, 253, 254, 267, 335–337,
340, 344–347, 351, 357, 358, 368, 395, 400,
406–408, 411, 414–420, 424, 425, 427, 428,
431, 432, 442, 470, 471, 485, 486, 490, 501,
504, 507, 510, 515, 519, 521, 522, 526,
528–531, 537, 538, 541–546, 549, 550, 556,
559–573, 575, 576
Antigen delivery ................................................... 461–474
Antigen production................................. 78, 95–117, 461
Antigens................................................ 3–7, 9–11, 19, 20,
30, 43–58, 63–79, 83–93, 119–134, 206, 223,
250, 252–256, 258, 259, 305–311, 313–328,
395, 400, 405, 414, 419–421, 423, 425, 426,
428, 431, 432, 439, 440, 448, 461, 462,
465–467, 469, 470, 473, 474, 477–486, 489,
492–494, 496, 501–504, 507, 509, 513–523,
526, 531, 534, 537, 538, 540, 541, 544, 546,
550, 551
Antigen-specific ......................................20, 21, 419, 428,
490, 513, 514, 525–535, 537–546, 550
Antigen-specific CD8+ T cell killing............................ 550
Antigen uptake ..................................................... 462, 514
Attenuation.............................2, 252, 259, 260, 331–353
B
Bacteria .......................2, 3, 7, 11, 16, 19, 20, 44, 52–55,
107, 191, 193, 249, 250, 252–256, 259, 267,
268, 276, 331, 333, 342, 343, 413, 420, 429,
450–452, 458, 461, 462, 472, 478, 479, 559–573
Baculovirus expression vector system
(BEVS) ....................................... 95–117, 368, 376
B-cell ....................... 4, 5, 25–27, 43, 45, 53, 56, 84, 559
Biomaterials .......................................................... 461, 462
C
Cancer vaccines ..............................................65, 256, 305
Capsular polysaccharide (CPS)................... 253, 254, 478
Capsule polymerases ............................................ 313–328
Carrier protein.................................... 267–303, 305–311,
313, 315, 477
Cell cultivation ...........................101, 106, 108, 112, 376
Cell-penetrating peptides (CPPs) ...............................358,
359, 364
Cell recruitment ................................................... 513–523
Cell therapy ................................................................... 369
Cellular immunity ............................................5, 415, 448
Centrifugation ................................. 69, 87, 89, 184, 189,
191, 193, 194, 197, 198, 210, 220, 226, 231,
239, 243, 276, 280, 327, 342, 348, 371, 380,
385, 433, 468, 470, 472, 480, 483, 485, 522,
571, 572, 584
Chlamydia.........................................................19, 20, 257
Chromatography ....................................75, 76, 120, 121,
123, 126–128, 133, 189, 199, 212, 220–222,
235, 236, 240, 241, 268, 271, 273, 274, 281,
301, 302, 316, 317, 328, 333, 342, 371, 474
Codon optimization ...........................199, 406, 411, 420
Computational antigen discovery ............................29–41
Conjugated vaccines ..................................................... 254
Conjugation ............................................. 6, 12, 267–302,
305–311, 363, 478
Cryogenic TEM (cryo-TEM)............................. 499–501,
503–510
Cytotoxicity .......................................................... 549–558
Cytotoxic T lymphocyte (CTL) ......................... 407, 420,
550–552, 554
D
Dicarboxylic acid linkers ...................................... 306–308
Dielectric spectroscopy (DS) ................................ 96, 102,
106, 218, 220, 232, 233, 239
Diseases........................................1, 2, 6, 7, 48, 117, 249,
251–254, 256, 257, 259, 260, 313, 331, 332,
367, 369, 370, 391, 407, 421, 424, 448, 461,
473, 477, 478, 494, 513, 525, 537, 559, 576
DNA delivery ................................................................ 448
DNA vaccines ............................ 357, 391–402, 405–421,
439–442, 444, 448
Blaine A. Pfeifer and Andrew Hill (eds.), Vaccine Delivery Technology: Methods and Protocols, Methods in Molecular Biology,
vol. 2183, https://doi.org/10.1007/978-1-0716-0795-4, © Springer Science+Business Media, LLC, part of Springer Nature 2021
587